The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | NKTR-255 in R/R MM and NHL
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, outlines a phase I, dose escalation and expansion study (NCT04136756) of NKTR-255, a polymer-conjugated IL-15, as a single agent in relapsed/refractory multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), plus in combination with daratumumab as a salvage regimen for MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
